Drug Combination Details
| General Information of the Combination (ID: C44803) | |||||
|---|---|---|---|---|---|
| Name | Matrine NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| In-vivo Model | Six-weeks-old BALB/c nude mice were subcutaneously injected with a 200 L cell suspension containing 5*106 HepG2 cells into the axillary region. | |||||
| Experimental
Result(s) |
The combination of matrine and cisplatin may promote tumor cell apoptosis in liver cancer by activating the caspase apoptosis pathway and suppressing the survivin-associated inhibition of caspase-9. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Effects of matrine in combination with cisplatin on liver cancer. Oncol Lett. 2021 Jan;21(1):66. | |||
